iRhythm Technologies logo

iRhythm TechnologiesNASDAQ: IRTC

Profile

Sector:

Healthcare

Country:

United States

IPO:

20 October 2016

Next earnings report:

21 February 2025

Last dividends:

N/A

Next dividends:

N/A
$2.55 B
-49%vs. 3y high
83%vs. sector
-vs. 3y high
-vs. sector
-11%vs. 3y high
99%vs. sector
-68%vs. 3y high
59%vs. sector

Price

pre-market | 33 min ago
$81.49+$1.66(+2.08%)

Dividend

No data over the past 3 years
$147.54 M$157.33 M
$147.54 M-$46.18 M

Analysts recommendations

Institutional Ownership

IRTC Latest News

iRhythm Data Presented at the American Heart Association 2024 Scientific Sessions Reinforce Clinical and Health Economic Value of Zio Long-Term Continuous Monitoring
globenewswire.com18 November 2024 Sentiment: -

Five new studies span three focus areas for LTCM devices: digital engagement and patient satisfaction, arrhythmia patterns during sleep and activity, and the potential health care resource and economic impact of early arrhythmia detection in patients with type 2 diabetes and COPD Five new studies span three focus areas for LTCM devices: digital engagement and patient satisfaction, arrhythmia patterns during sleep and activity, and the potential health care resource and economic impact of early arrhythmia detection in patients with type 2 diabetes and COPD

iRhythm Technologies to Participate in the Wolfe Research 2024 Healthcare Conference
globenewswire.com05 November 2024 Sentiment: POSITIVE

SAN FRANCISCO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, announced today that the company will be participating in the upcoming Wolfe Research 2024 Healthcare Conference.

iRhythm Technologies, Inc. (IRTC) Q3 2024 Earnings Call Transcript
seekingalpha.com30 October 2024 Sentiment: NEUTRAL

iRhythm Technologies, Inc. (NASDAQ:IRTC ) Q3 2024 Results Conference Call October 30, 2024 4:30 PM ET Company Participants Stephanie Zhadkevich - Director, Investor Relations Quentin Blackford - President and CEO Daniel Wilson - Chief Financial Officer Conference Call Participants Allen Gong - JPMorgan Macauley Kilbane - William Blair Kallum Titchmarsh - Morgan Stanley Marie Thibault - BTIG LLC David Ryman - Goldman Sachs David Rescott - Baird Richard Newitter - Truist William Plovanic - Canaccord Genuity Suraj Kalia - Oppenheimer Operator Hello, everyone, and welcome to iRhythm's Third Quarter 2024 Earnings Call. My name's Lydia, and I'll be your operator today.

IRhythm Technologies (IRTC) Reports Q3 Loss, Tops Revenue Estimates
zacks.com30 October 2024 Sentiment: NEUTRAL

IRhythm Technologies (IRTC) came out with a quarterly loss of $1.26 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to loss of $0.89 per share a year ago.

iRhythm Technologies Receives FDA 510(k) Clearance for Design Modifications to Its Zio® AT Device
globenewswire.com30 October 2024 Sentiment: POSITIVE

Zio AT device, along with the Zio ECG Utilization Software (ZEUS) (K222389), enables the provision of ambulatory Mobile Cardiac Telemetry (MCT) monitoring service for non-critical care patients

Newly Published Research Shows 14-Day Monitoring Detected Almost Three Times More Nonsustained Ventricular Tachycardia Than Standard 48-Hour Monitoring in Patients with Hypertrophic Cardiomyopathy
globenewswire.com28 October 2024 Sentiment: POSITIVE

SAN FRANCISCO, Oct. 28, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health company focused on creating trusted solutions that detect, predict, and prevent disease, today announced that the results of the Extended Ambulatory ECG Monitoring Enhances Identification of Higher-Risk Ventricular Tachyarrhythmias in Patients with Hypertrophic Cardiomyopathy (EXAMINE-HCM) study have been published in Heart Rhythm Journal . The findings were also presented at the Heart Rhythm Society's annual meeting in 2023, and most recently, at the International HCM Summit 8 in Boston, MA (October 25-28, 2024).

With FDA Approval iRhythm May Be Able To Lift Regulatory Overhang, Investor Skepticism, Analyst Says
benzinga.com22 October 2024 Sentiment: POSITIVE

On Monday, the FDA approved iRhythm Technologies, Inc.'s IRTC 510(k) submission related to prior design changes to the Zio AT device via letter to file.

iRhythm Technologies Stock Rises Post FDA Clearance for Zio AT
zacks.com22 October 2024 Sentiment: POSITIVE

IRTC receives FDA 510(k) clearance for prior design modifications to its Zio AT device, reinforcing its commitment to quality and compliance.

Kaskela Law LLC Announces Shareholder Investigation of iRhythm Technologies, Inc. (NASDAQ: IRTC) and Encourages Long-Term IRTC Shareholders to Contact the Firm
globenewswire.com20 September 2024 Sentiment: NEGATIVE

PHILADELPHIA, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating iRhythm Technologies, Inc. (NASDAQ: IRTC) (“iRhythm”) on behalf of the company's long-term shareholders.

iRhythm's Zio ECG System Gets Approval in Japan, Stock Falls
zacks.com13 September 2024 Sentiment: POSITIVE

IRTC's Zio ECG monitoring system gets approval in Japan, marking a significant step in revolutionizing arrhythmia diagnostics with AI-powered technology.

  • 1(current)
  • 2

What type of business is iRhythm Technologies?

iRhythm Technologies, Inc. is a digital company serving the healthcare industry. It is a provider of ECG ambulatory monitoring solutions for patients at risk of arrhythmias - portable Zio service biosensors with cloud data analysis. It is a vertically integrated company headquartered in San Francisco, California. The company was founded on September 14, 2006. The company's flagship product is the Zio service platform, which provides a wide range of capabilities for ambulatory heart monitoring. The platform combines a convenient and unobtrusive biosensor for wearing (up to 14 consecutive days) with powerful patented algorithms that turn data from a million heartbeats into clinically actionable information.

What sector is iRhythm Technologies in?

iRhythm Technologies is in the Healthcare sector

What industry is iRhythm Technologies in?

iRhythm Technologies is in the Medical Devices industry

What country is iRhythm Technologies from?

iRhythm Technologies is headquartered in United States

When did iRhythm Technologies go public?

iRhythm Technologies initial public offering (IPO) was on 20 October 2016

What is iRhythm Technologies website?

https://www.irhythmtech.com

Is iRhythm Technologies in the S&P 500?

No, iRhythm Technologies is not included in the S&P 500 index

Is iRhythm Technologies in the NASDAQ 100?

No, iRhythm Technologies is not included in the NASDAQ 100 index

Is iRhythm Technologies in the Dow Jones?

No, iRhythm Technologies is not included in the Dow Jones index

When was iRhythm Technologies the previous earnings report?

No data

When does iRhythm Technologies earnings report?

The next expected earnings date for iRhythm Technologies is 21 February 2025